Time-to-treatment failure and peripheral eosinophils in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Osawa, Hajime; Shiozawa, Toshihiro; Okauchi, Shinichiro; Miyazaki, Kunihiko; Kodama, Takahide; Kagohashi, Katsunori; Nakamura, Ryota; Satoh, Hiroaki; Hizawa, Nobuyuki

doi:10.20452/pamw.16049

Cited by 10 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to improved clinical outcomes, the increase in eosinophil counts after initiation of ICIs was also reported to be an early biomarker for the development of immune-related adverse events (irAEs). Osawa et al found that peripheral eosinophilia (defined as AEC ≥ 330/µL) at week 6 was associated with a 2.8-fold higher risk of irAEs [ 46 ]. Studies have observed such associations in ICI-induced adrenal insufficiency [ 47 ], hypopituitarism [ 48 ], cutaneous irAEs [ 49 ], and pneumonitis [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Chen

Tucker

Brown

et al. 2022

Cancers

View full text Add to dashboard Cite

A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/nivolumab (ipi/nivo) initiation and treatment responses in mRCC. A retrospective study of ipi/nivo-treated mRCC at two US academic cancer centers was conducted. A landmark analysis at week 6 was performed to assess the association between the change in NER and clinical responses (progression-free survival (PFS)/overall survival (OS)). Week 6 NER was modeled as a continuous variable, after log transformation (Ln NER), and a categorical variable by percent change. There were 150 mRCC patients included: 78% had clear cell histology, and 78% were IMDC intermediate/poor risk. In multivariable regression analysis, every decrease of 1 unit of Ln NER at week 6 was associated with improved PFS (adjusted hazard ratio (AHR): 0.78, p-value:0.005) and OS (AHR: 0.67, p-value: 0.002). When NER was modeled by percent change, decreased NER > 50% was associated with improved PFS (AHR: 0.55, p-value: 0.03) and OS (AHR: 0.37, p-value: 0.02). The decrease in week 6 NER was associated with improved PFS/OS in ipi/nivo-treated mRCC. Prospective studies are warranted to validate NER change as a biomarker to predict ICI responses.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Chen

Tucker

Brown

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…possibly due to the small number of participants. A previous study showed that the time to treatment failure and the survival time were longer in patients with a higher eosinophil level during ICI treatment and at baseline (21,26,34). The potential mechanism may be that eosinophils strengthened the antitumor response by normalizing the tumor vessels and enhancing the infiltration of CD8(+) T cells in caner tissues (35,36).…”

Section: Discussionmentioning

confidence: 99%

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis

Liu

Jia²,

Du³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

IntroductionCheckpoint inhibitor pneumonitis (CIP) is a common serious adverse event caused by immune checkpoint inhibitors (ICIs), and severe CIP can be life-threatening. We aimed to investigate the role of peripheral blood cells in diagnosis, prediction, and prognosis evaluation for all and severe CIP.Materials and methodsPatients with lung cancer receiving ICIs were enrolled in this retrospective study. Baseline was defined as the time of ICI initiation, endpoint was defined as the time of clinical diagnosis of CIP or the last ICI treatment, and follow-up point was defined as 1 week after CIP. Eosinophil percentages at baseline, endpoint, and follow-up point were shortened to “Ebas”, “Eend and “Efol”, respectively.ResultsAmong 430 patients included, the incidence of CIP was 15.6%, and severe CIP was 3.7%. The Eend/Ebas value was lower in patients with CIP (p = 0.001), especially severe CIP (p = 0.036). Receiver operating characteristic curves revealed that Eend/Ebas could serve as a biomarker to diagnose CIP (p = 0.004) and severe CIP (p < 0.001). For severe CIP, the eosinophil percentage declined before the symptoms appeared and CT diagnosis. The eosinophil percentage significantly elevated at the follow-up point in the recovery group but not in the non-recovery group. The CIP patients with Efol/Ebas ≥1.0 had significantly prolonged overall survival (p = 0.024) and after-CIP survival (AS) (p = 0.043). The same results were found in severe CIP but without a statistical difference.ConclusionsEosinophil percentage was associated with the diagnosis, prediction, and prognosis of CIP and severe CIP.

show abstract

“…cancer patients. 15,17 In NSCLC patients, ICI therapy only induces an early increase in blood eosinophils, which is more prominent in responding patients. 16 An increased REC during ICI therapy correlated with more objective responses.…”

Section: Discussionmentioning

confidence: 99%

“…14 In lung cancer patients, ICI-treated NSCLC patients with eosinophilia during treatment had higher response rates (RR) and more prolonged treatment durations. [15][16][17][18] OS is the most robust indicator of cancer treatment outcomes. Nevertheless, the relationship between an increased REC and OS in lung cancer patients treated with ICIs has not yet been examined in detail.…”

Section: Introductionmentioning

confidence: 99%

An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Takeuchi,

Ogino,

Kondo

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundAn increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).MethodsWe retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.ResultsA total of 151 patients with a mean age of 69 years were included. REC after 4 weeks of initial ICI monotherapy was higher than pretreatment REC in 87 patients but not in 64. REC after 4 weeks of the ICI treatment with and without an increased REC were 4.4 and 1.8%, respectively (p < 0.001). Disease control rates (DCR) were significantly higher in patients with than in those without an increased REC (84% vs. 47%, p < 0.001). The median overall survival (OS) of lung cancer patients with or without an increased REC were 674 and 234 days, respectively. A Kaplan–Meier univariate analysis revealed a significant difference in OS between the two groups (p < 0.001). A Cox proportional regression analysis identified an increased REC as an independent predictor of OS (p = 0.003).ConclusionICI‐treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined.

show abstract

Time-to-treatment failure and peripheral eosinophils in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Cited by 10 publications

References 37 publications

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis

An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About